Curtis Chong, MD
Medical Oncology · Palo Alto, CANPI 1912167420
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Foundation Medicine, Inc. accounts for 87.6% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2023 at $43,816 and has fallen 97.2% since, to $1,226 in 2025.
Across 81 payments — averaging $1222.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Foundation Medicine, Inc.$87K
- AstraZeneca$5K
- Vertex$1K
- Beigene USA, Inc.$1K
- Sanofi$864
- GSK$601
- plus $4K from 29 others
Across 13 payments — averaging $7516.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$62K
- Incyte Corporation$23K
- E.r. Squibb & Sons, L.L.C.$12K
What the payments were for
- Consulting fees$55,48756%
- Speaking & faculty fees$42,10743%
- Food & beverage$1,1111%
- Education$2980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Foundation Medicine, Inc. | 7 | $86,761 |
| AstraZeneca(2 entities) | 9 | $4,582 |
| Vertex | 2 | $1,050 |
| Beigene USA, Inc. | 2 | $1,017 |
| Sanofi | 8 | $864 |
| GSK | 6 | $601 |
| Lantheus Medical Imaging, Inc. | 1 | $550 |
| BD | 1 | $508 |
| Beigene, Ltd. | 1 | $500 |
| Tersera Therapeutics LLC | 1 | $452 |
| Halozyme Inc | 1 | $380 |
| Dr.reddy's Laboratories,inc. | 1 | $260 |
| Daiichi Sankyo Inc. | 2 | $223 |
| Leica Microsystems Inc. | 1 | $213 |
| Johnson & Johnson | 4 | $147 |
| Pfizer | 8 | $140 |
| Bayer | 1 | $124 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Bristol Myers Squibb | 3 | $87 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $59 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Seagen Inc. | 2 | $43 |
| Eisai Inc. | 2 | $41 |
| Astellas Pharma US Inc | 1 | $30 |
| ADC Therapeutics America, Inc. | 1 | $26 |
| Amgen | 1 | $23 |
| AbbVie | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Merck | 1 | $19 |
| Dova Pharmaceuticals | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOUNDATIONONE CDX$86,761
- FOUNDATIONONE LIQUID CDX$40,649
- FOUNDATIONONE LIQUID$33,116
- FOUNDATIONFOCUS$33,116
- FOUNDATIONONE HEME$33,116
- FOUNDATIONONE$33,116
- LYNPARZA$2,866
- IMFINZI$1,388
- BRUKINSA$1,000
- MARGENZA$452
- ZEJULA$425
- CABLIVI$350
- Vitrakvi$124
How this compares
$99,002 in reported general payments places this provider in the 80th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StivargaRegorafenib | 23 | $343,566 |
| CreonLipase/Protease/Amylase | 54 | $102,616 |
| EliquisApixaban | 80 | $77,066 |
| ZarxioFilgrastim-Sndz | 26 | $34,790 |
| XareltoRivaroxaban | 24 | $22,994 |
| Enoxaparin Sodium | 51 | $11,332 |
| JardianceEmpagliflozin | 13 | $10,218 |
| Mirtazapine | 50 | $1,976 |
| Sucralfate | 14 | $1,652 |
| Ondansetron Hcl | 118 | $1,494 |
| Prochlorperazine Maleate | 136 | $1,381 |
| Sodium Chloride0.9 % Sodium Chloride | 35 | $1,223 |
| Naloxone Hcl | 21 | $1,067 |
| Nystatin | 18 | $1,017 |
| Gabapentin | 71 | $928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerStivarga | $124 | $343,56623 claims |
| AbbVieCreon | $22 | $102,61654 claims |
| PfizerEliquis | $140 | $77,06680 claims |
| Johnson & JohnsonXarelto | $147 | $22,99424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 379 medical oncology providers in California.
Other medical oncology in Palo Alto
- Ann LowePalo Alto$923K
- Millie DasPalo Alto$152K
- Milana DolezalPalo Alto$135K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Marin XavierSan Diego$919K
- Munveer Bhangoola Jolla$804K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.